Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by scarlet1967on Oct 30, 2020 10:55am
113 Views
Post# 31812732

RE:RE:Stepped up their Corporate Presentation Game

RE:RE:Stepped up their Corporate Presentation GameAs Wino and others suggested HIV liver due to ART is harder to treat.
"First-in-class MOA with an upstream approach to underlying causes of NASH De-risked, late stage clinical program with demonstrated proof-of-concept Statistically significant results in a harder-to-treat patient population, driving optimism for efficacy in a broader, non-HIV patient population"
I really like these statement.
"120+ years of management experience, R&D engine of expert scientists,5.4M F2/F3NASH Patients in US only in 2019 and by 2030 10.6M F2/F3 NASH Patients" and of course great to see a slide with other NASH players.
They did a much better job advetising the legacy drugs too now get that application filed please.
 
SPCEO1 wrote: Wino - you should be trying to figure out where/how you collect your consulting check from TH!

That is a first class corporate presentation - what we have been lookng for has finally arrived. 

SPCEO1 wrote: Check out the new corporate presenatation - big improvement!

https://www.theratech.com/investisseurs/presentations-et-evenements/ew corporate presentation - big improvement!




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse